Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas

Histone deacetylase inhibitors are promising agents for various T-cell lymphomas, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and adult T-cell lymphoma/leukemia. CCR4 is an important therapeutic target molecule because mogamulizumab, an anti-CCR4 antibody, has shown promising ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitadate, Akihiro, Ikeda, Sho, Abe, Fumito, Takahashi, Naoto, Shimizu, Norio, Matsue, Kosei, Tagawa, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777200/
https://www.ncbi.nlm.nih.gov/pubmed/29025909
http://dx.doi.org/10.3324/haematol.2017.177279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777200/
https://www.ncbi.nlm.nih.gov/pubmed/29025909
http://dx.doi.org/10.3324/haematol.2017.177279

Ejemplares similares